Seminar on the Future of Oncology Biomarkers

Metropolitan Hotel, Tel Aviv
Monday, 22 May 2017, 8:30-16:00

8:30-9:10 Arrival and registration

9:10-9:30 Welcome by Dr. Per Spindler (Biopeople) and the Danish Minister of Science & Higher Education Søren Pind

9:30-10:15 Professor Estrid Høgdall, Director of the Danish Cancer Biobank and Head of the Molecular Unit, Herlev University Hospital: "Oncology biomarker development through basic research, biobanks and registers"

10:15-11:00 Dr. Yehudit Cohen, Director of Israel National Biobank MIDGAM: "Oncology biomarker development through basic research and biobanks"

11:00-11:15 Coffee Break

11:15-12:00 Prof. Claus Lindbjerg Andersen, Professor at Department of Molecular Medicine at University Hospital of Skejby and University of Aarhus: "From screening biomarkers to diagnostics in cancer"

12:00-12:30 Dr. Iris Grossmann, Head of Personalized & Predictive Medicine and Big Data Analytics at Teva Pharmaceuticals: "Employing cutting-edge biomarker research and Big Data analytics to drive decision making that improves the benefit-risk profile of specialty, generic and technologies"

12:30-14:00 Lunch

14:00-15:30 Parallel Roundtables

Roundtable 1: Thematic on Oncology biomarker development through basic research, biobanks and registers. Co-moderators: Professor Nils Brünner, University of Copenhagen and Dr. Dana Cohen, BioJerusalem and Zotal

Roundtable 2: Thematic on screening markers through companion diagnostics in cancer. Co-Moderators: Dr. Peter Buhl Jensen, Medical Prognosis Institute and Oncology Venture and Dr. Yoav Manaster, Co-founder, Progenetics

15:30-16:00 Presentation of roundtables (5 min by each moderator) followed by plenum Q&A and discussion. Chair: Kim Holmstrøm, Co-founder of The Danish Biomarker Network and R&D Manager, Bioneer

16:00 Farewell